Dianthus Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) is a clinical-stage biotechnology company dedicated to developing next-generation complement therapeutics to transform the treatment of severe, antibody-mediated autoimmune and inflammatory diseases. The company's lead product candidate is claseprubart (DNTH103), a highly selective monoclonal antibody designed to target active C1s in the classical complement pathway. By selectively inhibiting active C1s, claseprubart aims to deliver robust efficacy with a highly convenient, low-volume, subcutaneous self-injection dosing profile (e.g., every two or four weeks), potentially expanding the therapeutic category in neuromuscular diseases. Dianthus is also developing DNTH212, a bifunctional fusion protein targeting plasmacytoid dendritic cells (pDC) BDCA2 and inhibiting BAFF/APRIL, to establish a second franchise in rheumatology.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead candidate, claseprubart (DNTH103), across multiple high-value neuromuscular indications including generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
Expected impact: Establishes a leading clinical position in complement-mediated neuromuscular diseases, potentially supporting multiple BLA filings.
Developing DNTH212, a bifunctional BDCA2 and BAFF/APRIL inhibitor, for severe autoimmune diseases, prioritizing Sjögren's Disease (SjD), Systemic Lupus Erythematosus (SLE), and Dermatomyositis (DM).
Expected impact: Expands the pipeline beyond complement inhibitors into dual-targeting biologics for systemic autoimmune disorders.
Maintaining a disciplined spending approach and leveraging public offerings to secure a robust cash position to fund long-term clinical development.
Expected impact: Secures a cash runway into 2030 following a $719 million public offering in March 2026, reducing financing risk during key clinical readouts.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Grants Dianthus exclusive rights to develop and commercialize DNTH212 globally outside of Greater China, establishing its rheumatology pipeline.
Terms: Up to $38 million in upfront and near-term milestones (including $30 million upfront/near-term and $8 million Phase 1 milestone), plus up to $962 million in subsequent development, regulatory, and sales milestones, and tiered royalties.
Novated from Zenas BioPharma, transferring rights for development and commercialization of antibody sequences in Greater China.
Terms: Cumulative milestones of $7.0 million achieved as of March 31, 2026, with eligibility for future milestones and mid-single to low-double digit royalties on net sales.